Zenara Pharma Secures First Generic Sertraline Capsule Approval with 180-Day Market Exclusivity
Key Insights
Zenara Pharma (search) received FDA approval for the first generic version of Sertraline Hydrochloride Capsules in 150 mg and 200 mg strengths, marking a significant milestone in psychiatric medication accessibility.
The approval includes Competitive Generic Therapy designation, granting Zenara 180 days of exclusive marketing rights in the U.S. market.
The generic sertraline capsules are indicated for treating Major Depressive Disorder (search) in adults and Obsessive-Compulsive Disorder (search) in both adults and pediatric patients aged six years and older.
Zenara Pharma (search) Private Limited, a Biophore (search) company, has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Sertraline Hydrochloride Capsules in 150 mg and 200 mg strengths. This approval represents the first FDA-approved generic equivalent of the reference listed drug marketed by Almatica Pharma (search), LLC.
Competitive Generic Therapy Designation Provides Market Advantage
The FDA has granted Zenara's product Competitive Generic Therapy (CGT) designation, positioning the company as the first approved applicant under this pathway. This designation has secured 180 days of marketing exclusivity in the U.S. market, which commenced with the product's launch.
The CGT designation is part of the FDA's efforts to encourage competition in markets where generic alternatives are limited, ultimately benefiting patients through increased access to affordable medications.
Clinical Applications and Patient Population
Sertraline Hydrochloride Capsules are classified as selective serotonin reuptake inhibitors (SSRIs) and carry indications for treating Major Depressive Disorder (search) in adults and Obsessive-Compulsive Disorder (search) in both adults and pediatric patients aged six years and older.
According to IQVIA sales data for the 12-month period ending June 2025, U.S. sales of the reference product totaled approximately $35.5 million, indicating a substantial market opportunity for the generic version.
Company Leadership Perspective
Dr. Srinivas Arutla, CEO of Zenara Pharma (search) Pvt. Ltd., emphasized the significance of this achievement: "Receiving the first generic approval for Sertraline Hydrochloride Capsules highlights Zenara's strong R&D capabilities and operational excellence. We remain committed to our mission of delivering to patients, early access to high-quality, affordable pharmaceuticals."
Strategic Focus Areas
Zenara Pharma (search) operates as a vertically integrated pharmaceutical company committed to delivering high-quality, safe, effective, and affordable pharmaceuticals to patients. The company maintains focus on multiple therapeutic areas including Neurology, Orphan Drugs, Complex Products, Women's health, Cardiology, Imaging, and Contrast Agents.